Logo image of CLIN

CLEAN EARTH ACQUISITIONS -A (CLIN) Stock Fundamental Analysis

NASDAQ:CLIN - Nasdaq - US1844931048 - Common Stock - Currency: USD

5  -0.7 (-12.28%)

After market: 3.99 -1.01 (-20.2%)

Fundamental Rating

2

CLIN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 0 industry peers in the Unkown industry. While CLIN seems to be doing ok healthwise, there are quite some concerns on its profitability. CLIN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CLIN was profitable.
CLIN had a positive operating cash flow in the past year.
CLIN Yearly Net Income VS EBIT VS OCF VS FCFCLIN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 0 -500K -1M

1.2 Ratios

Industry RankSector Rank
ROA 4.82%
ROE 5.11%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CLIN Yearly ROA, ROE, ROICCLIN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 0 -0.1 -0.2 -0.3 -0.4

1.3 Margins

CLIN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLIN Yearly Profit, Operating, Gross MarginsCLIN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, CLIN has more shares outstanding
CLIN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CLIN Yearly Shares OutstandingCLIN Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 10M 20M 30M
CLIN Yearly Total Debt VS Total AssetsCLIN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 11.24 indicates that CLIN is not in any danger for bankruptcy at the moment.
CLIN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 11.24
ROIC/WACCN/A
WACCN/A
CLIN Yearly LT Debt VS Equity VS FCFCLIN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 0 50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 17.61 indicates that CLIN has no problem at all paying its short term obligations.
A Quick Ratio of 17.61 indicates that CLIN has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 17.61
Quick Ratio 17.61
CLIN Yearly Current Assets VS Current LiabilitesCLIN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 50M 100M 150M 200M

More info and screens

0

3. Growth

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 35.71, the valuation of CLIN can be described as expensive.
CLIN's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 24.85.
Industry RankSector Rank
PE 35.71
Fwd PE N/A
CLIN Price Earnings VS Forward Price EarningsCLIN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF 36.3
EV/EBITDA N/A
CLIN Per share dataCLIN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CLIN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLEAN EARTH ACQUISITIONS -A

NASDAQ:CLIN (12/22/2023, 8:20:54 PM)

After market: 3.99 -1.01 (-20.2%)

5

-0.7 (-12.28%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners1.2%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap83.50M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 35.71
Fwd PE N/A
P/S N/A
P/FCF 36.3
P/OCF 36.3
P/B 1.03
P/tB 1.03
EV/EBITDA N/A
EPS(TTM)0.14
EY2.8%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.14
FCFY2.75%
OCF(TTM)0.14
OCFY2.75%
SpS0
BVpS4.87
TBVpS4.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 4.82%
ROE 5.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 55.29%
Current Ratio 17.61
Quick Ratio 17.61
Altman-Z 11.24
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A